GSK buys liver disease drug
GSK acquires efimosfermin, a drug candidate for the liver disease MASH, from Boston Pharmaceuticals for USD 1,2 billion. The drug is ready for Phase III studies and, if all goes well, could be launched in 2029. The agreement includes up to USD 800 million in milestone payments. Efimosfermin, a monthly injection, has shown promising results in reducing liver fibrosis and GSK plans to develop the drug for alcoholic liver disease.
Notes
Alligator Bioscience receives FDA approval for phase III mitazalimab dose
Lena Åredal appointed new CEO of SyntheticMR
BioArctic advances phase IIa study with exidavnemab
Novo Nordisk advances amycretin to Phase III
BioNTech acquires CureVac for $1,25 billion
ALZ-101 shows stable antibody levels in the brain
Isofol completes first cohort in arfolitixorin study
NEWSLETTER
Upcoming events
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Recommended
Biotech funding plummets in the wake of Trump's policies
700 million euros allocated to Nordic life science
BioNTech and Bristol Myers Squibb sign monster deal
From the LSD of the 60s to the JRT of the future
The pharmaceutical industry's call to the EU: Act!
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
